Menopausal hormone therapy (MHT) is the treatment of choice for climacteric and particularly
vasomotor symptoms [
[1]
]. Current guidelines advise that treatment should be individualized according to
the characteristics of the patient, including cardiovascular and cancer risk assessment.
In general, combined therapy with estrogen and a progestogen is indicated for women
with an intact uterus, whereas estrogen monotherapy is considered for hysterectomized
women. [
[1]
]To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).Maturitas. 2016; 89: 63-72
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials.Jama. 2017; 318: 927-938
- Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials.JAMA oncology. 2015; 1: 296-305
- Breast cancer and hormone-replacement therapy in the Million Women Study.Lancet. 2003; 362: 419-427
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.Breast cancer research and treatment. 2008; 107: 103-111
- Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.International journal of cancer. 2005; 114: 448-454
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Lancet. 2019; 394: 1159-1168
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials.JAMA. 2020; 324: 369-380
- Progesterone, progestins and the breast in menopause treatment.Climacteric. 2018; 21: 326-332
- Progestogens in postmenopausal hormone therapy and the risk of breast cancer.Maturitas. 2014; 77: 311-317
- Progesterone and Breast Cancer.Endocr Rev. 2020; 41: 320-344
Article info
Publication history
Published online: August 12, 2020
Received:
July 31,
2020
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
